Hemophilia B - 26 Studies Found
| NOT_YET_RECRUITING |
: Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001 : Hemophilia B Without Inhibitor : 2025-08-03 : Subjects will be dosed with single dose of KL001 at 2.5x10^12 vg/kg. |
| Completed |
: Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) : Hemophilia B : 2025-08-03 : Adeno-associated viral vector carrying the FIX gene single infusion at dose 1. |
| Completed |
: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) : Hemophilia B : 2025-08-03 : Administered as a single IV infusion. |
| Completed |
: A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors : Hemophilia B With Inhibitor : 2025-08-03 : Administered as SC injection. |
| Completed |
: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX� in Patients With Hemophilia B : Hemophilia B : 2025-08-03 : HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia |
| COMPLETED |
: A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C?2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C?1%) : Hemophilia B : 2025-08-03 : There is no investigational product being administered.Subjects will be administering their own standard of care FIX replacement therapy. |